Summary & Overview
HCPCS Level II Q0519: Pharmacy Supply Fee for Injectable HIV PrEP, per 30 Days
HCPCS Level II code Q0519 denotes a pharmacy supplying fee for an FDA-approved injectable HIV pre-exposure prophylaxis (PrEP) prescription, billed per 30 days. This code captures the pharmacy service component tied to dispensing long-acting injectable PrEP agents and matters nationally as injectable PrEP becomes a more common prevention option. Proper use of Q0519 helps separate pharmacy dispensing fees from drug acquisition costs and supports accurate claims for prevention-focused services.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code's purpose, typical sites of service, and the clinical context for injectable PrEP. The publication also summarizes payer coverage patterns, common modifiers associated with billing this supply fee, and implications for coding workflows.
This overview is intended for billing professionals, pharmacy services, and policy analysts seeking clarity on how to represent the pharmacy supply component of injectable PrEP on claims. Data not available in the input is noted where applicable; the narrative focuses on national relevance, coding considerations, and the operational role of Q0519 in claims submissions for 30-day pharmacy supply fees.
Billing Code Overview
HCPCS Level II code Q0519 describes a pharmacy supplying fee for an HIV pre-exposure prophylaxis (PrEP) FDA-approved prescription injectable drug, billed per 30-days. This code reflects the supply-related pharmacy service associated with dispensing a long-acting injectable PrEP medication.
Service type: Pharmacy supply fee for injectable PrEP medication (per 30 days)
Typical site of service: Outpatient pharmacy or clinic-based pharmacy dispensing injectable PrEP for community or clinic patients
Clinical & Coding Specifications
Clinical Context
A 28-year-old cisgender man with multiple anonymous sexual partners presents to an outpatient infectious disease or sexual health clinic seeking HIV pre-exposure prophylaxis (PrEP). He has a recent negative HIV antigen/antibody test and normal renal function. The clinician prescribes an FDA-approved injectable long-acting cabotegravir formulation for HIV PrEP and sends the medication order to the clinic-associated pharmacy. The pharmacy dispenses the injectable product in a 30-day supply package and bills the dispensing fee using Q0519 for the pharmacy supplying fee per 30-days. Typical workflow steps: initial visit with risk assessment and baseline labs (HIV test, creatinine, hepatitis B status), prescription of the injectable PrEP product, pharmacy fulfillment and billing of the pharmacy supplying fee with Q0519, coordination with the clinic for administration scheduling, and follow-up monitoring visits for safety and adherence documentation. Typical sites of service include outpatient clinic pharmacies, community pharmacies, and specialty infusion or sexual health clinic pharmacies. Common patient scenarios include sexually active individuals at substantial risk for HIV, partners of people living with HIV, people who inject drugs, and those who prefer long-acting injectable PrEP over daily oral formulations. Documentation includes prescription, dispensing record, lot/expiration tracking, patient counseling note, and coordination of administration appointment.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|